Bone Marrow Transplantation - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Bone Marrow Transplantation - Pipeline Review, H1 2016', provides an overview of the Bone Marrow Transplantation pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bone Marrow Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Marrow Transplantation and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Bone Marrow Transplantation - The report reviews pipeline therapeutics for Bone Marrow Transplantation by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Bone Marrow Transplantation therapeutics and enlists all their major and minor projects - The report assesses Bone Marrow Transplantation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Bone Marrow Transplantation Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Bone Marrow Transplantation - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Bone Marrow Transplantation pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Bone Marrow Transplantation Overview 8 Therapeutics Development 9 Pipeline Products for Bone Marrow Transplantation - Overview 9 Pipeline Products for Bone Marrow Transplantation - Comparative Analysis 10 Bone Marrow Transplantation - Therapeutics under Development by Companies 11 Bone Marrow Transplantation - Therapeutics under Investigation by Universities/Institutes 12 Bone Marrow Transplantation - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Bone Marrow Transplantation - Products under Development by Companies 16 Bone Marrow Transplantation - Products under Investigation by Universities/Institutes 17 Bone Marrow Transplantation - Companies Involved in Therapeutics Development 18 Anchor Therapeutics, Inc. 18 Boryung Pharmaceutical Co., Ltd. 19 Cleveland BioLabs, Inc. 20 Compugen Ltd. 21 Mesoblast Limited 22 Pluristem Therapeutics Inc. 23 Taiga Biotechnologies, Inc. 24 Targazyme, Inc. 25 Bone Marrow Transplantation - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Combination Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 (filgrastim + plerixafor) - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 ATI-2341 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 BR-05001 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 CBLB-612 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Cellular Immunotherapy for Bone Marrow Transplantation - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 CGEN-15001 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 MPC-CBE - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 PLXR-18 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Protein for Bone Marrow Transplantation - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Small Molecules to Inhibit Perforin for Bone Marrow Transplantation - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 TZ-101 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Bone Marrow Transplantation - Recent Pipeline Updates 54 Bone Marrow Transplantation - Dormant Projects 65 Bone Marrow Transplantation - Discontinued Products 66 Bone Marrow Transplantation - Product Development Milestones 67 Featured News & Press Releases 67 Jan 12, 2016: Pluristem Receives U.S. FDA Clearance to Initiate Clinical Trial of PLX-R18 to Treat Insufficient Hematopoietic Recovery Following Bone Marrow Transplant 67 Nov 17, 2015: Pluristem to Present New Data on PLX-R18 at American Society of Hematology's Annual Meeting 67 May 06, 2015: Pluristem Granted European Patent for Use of Cells to Help Treat Damaged Bone Marrow 68 Mar 24, 2015: Pluristem Announces Key Strategic Objectives for Development of PLX-R18 in Hematopoietic Indications 68 Mar 03, 2015: Pluristem and Hadassah Medical Center Announce Significant Data Showing PLX-R18 Cells Improve Bone Marrow Transplantation 69 Dec 04, 2014: Pluristem and Hadassah Medical Center Will Collaborate to Study Potential of PLX-RAD Cells to Improve Bone Marrow and Umbilical Cord Blood Transplant Outcomes 71 Nov 13, 2014: Cell Source's Megadose Drug Combination Receives Regulatory Approval in Italy to Commence Human Clinical Trials 71 Oct 27, 2014: Case Western Reserve University to Study Pluristem's PLX-RAD Cells in Umbilical Cord Blood Transplants for the Treatment of Blood Cancers and Genetic Diseases 72 May 07, 2013: Pluristem Develops PLX-RAD Cells For Use In Hematology 73 Sep 05, 2012: Pluristem Therapeutics Announces Successfully Treatment Of Third Critically Ill Patient With PLX Cells Under Compassionate Use 74 Appendix 75 Methodology 75 Coverage 75 Secondary Research 75 Primary Research 75 Expert Panel Validation 75 Contact Us 75 Disclaimer 76
List of Tables
Number of Products under Development for Bone Marrow Transplantation, H1 2016 9 Number of Products under Development for Bone Marrow Transplantation - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Number of Products under Investigation by Universities/Institutes, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Development, H1 2016 15 Products under Development by Companies, H1 2016 16 Products under Investigation by Universities/Institutes, H1 2016 17 Bone Marrow Transplantation - Pipeline by Anchor Therapeutics, Inc., H1 2016 18 Bone Marrow Transplantation - Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2016 19 Bone Marrow Transplantation - Pipeline by Cleveland BioLabs, Inc., H1 2016 20 Bone Marrow Transplantation - Pipeline by Compugen Ltd., H1 2016 21 Bone Marrow Transplantation - Pipeline by Mesoblast Limited, H1 2016 22 Bone Marrow Transplantation - Pipeline by Pluristem Therapeutics Inc., H1 2016 23 Bone Marrow Transplantation - Pipeline by Taiga Biotechnologies, Inc., H1 2016 24 Bone Marrow Transplantation - Pipeline by Targazyme, Inc., H1 2016 25 Assessment by Monotherapy Products, H1 2016 26 Assessment by Combination Products, H1 2016 27 Number of Products by Stage and Target, H1 2016 29 Number of Products by Stage and Mechanism of Action, H1 2016 31 Number of Products by Stage and Route of Administration, H1 2016 33 Number of Products by Stage and Molecule Type, H1 2016 35 Bone Marrow Transplantation Therapeutics - Recent Pipeline Updates, H1 2016 54 Bone Marrow Transplantation - Dormant Projects, H1 2016 65 Bone Marrow Transplantation - Discontinued Products, H1 2016 66
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.